TROV Stock Soars 22% on Positive Mid-Stage Data at ESMO

TROV stock is one of the biggest biotech stock gainers this morning after TrovaGene Inc (NASDAQ:TROV) reported positive results from its Phase 1b/2 study of onvansertib.

Key Details

Companies in the therapeutics space strive for producing treatments for some of the most difficult health conditions in people, and any positive development about products in the pipeline is always welcome. Clinical stage oncology therapeutics company TrovaGene today made a major announcement with regards to its medicine that is meant for the treatment of relapsed/refractory acute myeloid leukemia (AML)—and the news has helped TROV stock.

The medicine in question is onvansertib, and the company presented the data from its Phase 1b/2 study at the European Society for Medical Oncology Conference (ESMO) held in Barcelona, Spain this past Saturday. The presentation made at the event stressed the effectiveness of the product as well as the safety that it provides to the patients.

In addition to that, TrovaGene also released correlative biomarker data from the tests, and that proved to be another significant positive overall.

The Chief Scientific Officer of the company, Dr. Mark Erlander spoke about the significance of the biomarker data: “We continue to be encouraged by our biomarker data which indicates a correlation between biomarker positive patients and their response to treatment with onvansertib.”

The company is already preparing for the next stage of testing that will be even more vital for the future of onvansertib and one that it needs to definitely get right. The medicine in question has to be consumed orally and has a half-life of around 24-hours.

TrovaGene has announced that it is going to recruit a total of 32 patients for the Phase 2 study of the medicine. Only patients who have completed at least a single cycle of treatment with onvansertib are going to be used for this particular phase of testing.

This is an important update from the company, and it remains to be seen what sort of effect the latest presentation ends up having on TROV stock going forward.

STOCKS YOU MAY LIKE

Biotech penny stocks are biotech stocks that sell for less than $5 per share. Most early-stage clinical biotech companies usually fall into the penny stock range. They are prone to market volatility and have large …

In the wake of the coronavirus pandemic, biotech stocks have been of interest to investors, given that they’re some of the top gainers in the past few weeks. In particular, low float biotech stocks have …

Those new to investing in the stock market tend to focus on large cap companies instead of small cap ones. However, Maria Ohle explains that there are plenty of reasons why one should consider investing …

Investors are almost always on the lookout for the latest penny stock gainers, but in the current situation, they need to look into companies far more carefully than before. The coronavirus pandemic has triggered an …

So far in March, stock markets have experienced massive losses as the coronavirus outbreak continues to wreak havoc on the global economy. The Dow Jones and S&P 500 plunged, prompting concerns that a global financial …

Biotech has been one of the fastest-growing sectors over the past half a decade or so, garnering a lot of interest in things like biotech penny stocks. Moreover, the onset of the coronavirus pandemic has …

In 1992, Congress passed the Prescription Drug User Fee Act (PDUFA), which allows the US Food and Drug Administration (FDA) to collect fees from drug manufacturers to fund the drug review and approval process. The …

2019 is almost over, and while some investors are reflecting on a successful year, others are scrambling to add value to their portfolio before the year wraps up. If you didn’t capitalize on the stock …